Sunshine Biopharma Inc.
No SEC Form 4 filings for $SBFM in the last 30 days.
See all $SBFM insider activity →Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s boar
Sunshine Biopharma Inc. (NASDAQ: SBFM) announced its lead coronavirus drug candidate has entered IND-enabling studies. The company reported nanomolar potency against viral protease, broad-spectrum activity against SARS-CoV-2 variants, and strong oral bioavailability in multiple species. The drug also showed dose-dependent suppression of pulmonary viral replication in vivo. According to the company, the candidate is preferentially enriched in the lungs of mice and rats.
Sunshine Biopharma (SBFM) advanced its lead coronavirus drug candidate into IND-enabling studies. The PLpro inhibitor showed nanomolar potency, broad in vitro activity against SARS-CoV-2 variants, and dose-dependent viral suppression in infected mice. The company reports high oral bioavailability and lung enrichment in multiple species. Sunshine Biopharma positions this as a differentiated antiviral program with scientific and commercial potential.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning SBFM (Sunshine Biopharma Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent SBFM coverage spans corporate actions, technology and regulation.
Reverse split could reduce float and increase share price per share, affecting liquidity and short‑interest dynamics.
Positive clinical progress may boost investor confidence and drive the stock higher.
Advancement to IND‑enabling studies suggests the candidate is moving toward clinical trials, potentially increasing valuation.
Warrant price reduction may improve the economics for warrant holders and could modestly support the stock by lowering dilution concerns.
Potential modest cash infusion but dilution risk may pressure the stock short term.
AlphAI scores every news story that mentions SBFM with an AI model for sentiment and relevance, and aggregates insider trades from Sunshine Biopharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s boar
1 min readSunshine Biopharma Inc. (NASDAQ: SBFM) announced its lead coronavirus drug candidate has entered IND-enabling studies. The company reported nanomolar potency against viral protease, broad-spectrum activity against SARS-CoV-2 variants, and strong oral bioavailability in multiple species. The drug also showed dose-dependent suppression of pulmonary viral replication in vivo. According to the company, the candidate is preferentially enriched in the lungs of mice and rats.
2 min readSunshine Biopharma (SBFM) advanced its lead coronavirus drug candidate into IND-enabling studies. The PLpro inhibitor showed nanomolar potency, broad in vitro activity against SARS-CoV-2 variants, and dose-dependent viral suppression in infected mice. The company reports high oral bioavailability and lung enrichment in multiple species. Sunshine Biopharma positions this as a differentiated antiviral program with scientific and commercial potential.
2 min readSunshine Biopharma (SBFM) reduced its Series B Warrant exercise price to $1.2046 due to recent common stock sales under an at-the-market offering. The adjustment reflects dilution mechanics and may impact investors holding these warrants. TipRanks' AI Analyst rates SBFM as Neutral, citing weak financials and bearish technicals.
1 min readSunshine Biopharma (SBFM) filed a registration statement for 25.5M shares of common stock issuable upon exercise of Series B Warrants, potentially raising $31.1M. The warrants have an exercise price of $1.2202 and expire in 2029. SBFM's stock last traded at $1.27 per share.
1 min readDr. Andrew Keller will not seek reelection to Sunshine Biopharma's board when his term ends at the next annual meeting. The company filed this update in an SEC 8-K form.
1 min readSunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 25, 2026, Dr. Andrew Keller, a director of Sunshine Biopharma Inc. (the “Company”), notified the Company that he
1 min readSunshine Biopharma (NASDAQ: SBFM) reported that its K1.1 mRNA therapy showed tumor-suppressing activity in liver cancer models. The company plans to combine it with a cancer vaccine to treat non-small cell lung cancer (NSCLC), aiming to convert 'cold' tumors into 'hot' tumors. The K1.1 mRNA targets a tumor suppressor frequently mutated in lung, pancreatic, and liver cancers.
2 min readSunshine Biopharma (SBFM) reported that its K1.1 mRNA lipid nanoparticle showed tumor-suppressing activity in liver cancer mouse models. The company plans to test the mRNA with a cancer vaccine in non-small cell lung cancer (NSCLC). SBFM's stock declined 6.14% following the announcement, trading at $1.07 with heavy volume.
2 min readSunshine Biopharma (SBFM) received Canadian approval for its generic Enalapril tablets, entering the antihypertensive drug market. The company plans to launch 12 more drugs in 2026 and expects shipments by year-end. The global antihypertensive market is projected to grow to $37.24B by 2034. SBFM shares rose 1.79% in premarket trading.
2 min read
